Lipegfilgrastim (Lonquex^®) is recommended as an option for restricted use within NHS Wales for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lipegfilgrastim (Lonquex®) should be restricted for use where a long-acting granulocyte colony-stimulating factor (G-CSF) is appropriate. Lipegfilgrastim (Lonquex®) is not recommended for use within NHS Wales outside of this subpopulation.